Merck & Co., Inc. (NYSE:MRK - Get Free Report) announced a quarterly dividend on Tuesday, November 17th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.88 per share on Friday, January 8th. This represents a $3.52 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Tuesday, December 15th. This is a 3.5% increase from Merck & Co., Inc.'s previous quarterly dividend of $0.85.
Merck & Co., Inc. has raised its dividend payment by an average of 0.1% per year over the last three years and has raised its dividend annually for the last 14 consecutive years. Merck & Co., Inc. has a dividend payout ratio of 35.0% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Merck & Co., Inc. to earn $9.08 per share next year, which means the company should continue to be able to cover its $3.40 annual dividend with an expected future payout ratio of 37.4%.
Merck & Co., Inc. Stock Down 1.0%
Shares of NYSE MRK opened at $143.01 on Wednesday. The company has a debt-to-equity ratio of 1.11, a current ratio of 1.35 and a quick ratio of 1.14. The company has a market cap of $352.56 billion, a P/E ratio of 147.43, a PEG ratio of 6.62 and a beta of 0.13. Merck & Co., Inc. has a 1 year low of $92.11 and a 1 year high of $156.92. The firm has a 50-day simple moving average of $145.93 and a two-hundred day simple moving average of $128.97.
Merck & Co., Inc. (NYSE:MRK - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.09 by $0.40. The business had revenue of $18.09 billion during the quarter, compared to analyst estimates of $17.33 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 3.64%. The company's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.58 earnings per share. Research analysts anticipate that Merck & Co., Inc. will post 2.82 earnings per share for the current year.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the company's stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at approximately $16,718,469.55. This represents a 34.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.17% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Merck & Co., Inc.
Institutional investors have recently made changes to their positions in the company. Curry Webb Wealth Management LLC purchased a new stake in shares of Merck & Co., Inc. in the 3rd quarter worth approximately $29,000. Horizons Wealth Management purchased a new position in Merck & Co., Inc. in the third quarter valued at about $30,000. Bullseye Investment Management LLC purchased a new position in shares of Merck & Co., Inc. in the 2nd quarter worth approximately $27,000. Clal Insurance Enterprises Holdings Ltd increased its position in shares of Merck & Co., Inc. by 69.5% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 222 shares of the company's stock worth $32,000 after purchasing an additional 91 shares in the last quarter. Finally, Graney & King LLC increased its position in Merck & Co., Inc. by 400.0% during the 2nd quarter. Graney & King LLC now owns 250 shares of the company's stock valued at $32,000 after buying an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company's stock.
About Merck & Co., Inc.
(
Get Free Report)
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company's research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Merck & Co., Inc., you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.
While Merck & Co., Inc. currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.